Comparison of the Effectiveness of Rivaroxaban Versus Vitamin K Antagonist in Patients with Lower Limbs Deep Vein Thrombosis
DOI:
https://doi.org/10.37762/jgmds.11-2.585Keywords:
: Vitamin K Antagonist, Rivaroxaban, Lower Limbs Deep Vein ThrombosisAbstract
OBJECTIVES
To compare the effectiveness of rivaroxaban and vitamin K antagonists in patients with lower limbs deep vein thrombosis.
METHODOLOGY
This quasi-experimental study was conducted in the Department of General Medicine in Khyber Teaching Hospital, Peshawar for six months with a sample size of sixty. Thirty patients were given Rivaroxaban (Group A) and the other thirty patients were given Vitamin K antagonist (Group B). In the Rivaroxaban group, patients had received 15mg twice daily for the first 3 weeks, 20 mg once daily from 3 weeks to 3 months, and followed by 10 mg once daily. In the Vitamin K antagonist group, patients had received a dose of warfarin of 2.5-5mg once daily, with a goal INR between 2-3. Patients were followed up for 3 months, every month and the effectiveness of both drugs was recorded.
RESULTS
Our study shows that in group A (Rivaroxaban), the mean age was 34 years with SD ± 10.77 and in group B (Vitamin K antagonist), the mean age was 36 years with SD ± 11.09. In Group A, 12(40%) patients were males and 18(60%) were females. In Group B, 11(37%) patients were males and 19(63%) were females. Moreover, group A was effective in 27(90%) patients while group B was effective in 25(83%).
CONCLUSION
Rivaroxaban is more effective than vitamin K antagonist in the treatment of lower limbs deep vein thrombosis.
Downloads
Metrics
References
Parker K, Thachil J. The use of direct oral anticoagulants in chronic kidney disease. Br J Haematol. 2018;183(2):170-84
Naringrekar H, Sun J, Ko C, Rodgers SK. It's not all deep vein thrombosis: sonography of the painful lower extremity with multimodality correlation. J Ultrasound Med. 2019;38(4):1075-89
Seifi A, Dengler B, Martinez P, Godoy DA. Pulmonary embolism in severe traumatic brain injury. J Clin Neurosci. 2018;57:46-50
Jones MA, Lee DY, Segall JA. Characterizing resolution of catheterassociated upper extremity deep venous thrombosis. J Vasc Surg. 2010;51:108-13.
Charles N, Bernstein, James F. Blanchard, Donald S. Houston, Andre Wajda. The incidence of Deep Vein Thrombosis and Pulmonary Embolism among patients with inflammatory bowel disease: A population-based Cohort study. Thrombosis and Haemostasis. 2001; 85(03): 430-434
Hansen AT, Juul S, Knudsen UB, Hvas AM. Low risk of venous thromboembolism following early pregnancy loss in pregnancies conceived by IVF. Hum Reprod. 2018;33(10):1968-72
Sharif S, Eventov M, Kearon C, Parpia S, Li M, Jiang R,et al. Comparison of the age-adjusted and clinical probability-adjusted D-dimer to exclude pulmonary embolism in the ED. Am J Emerg Med. 2019;37(5):845-50
Delluc A, Le Mao R, Tromeur C, Chambry N, Rault-Nagel H, Bressollette L, et al. Incidence of upper-extremity deep vein thrombosis in western France: a community-based study. Haematologica. 2019;104(1):e29-e31
Carroll BJ, Piazza G. Hypercoagulable states in arterial and venous thrombosis: when, how, and who to test? Vasc Med. 2018;23(4):388-99
Sun ML, Wang XH, Huang J, Wang J, Wang Y. Comparative study on deep venous thrombosis onset in hospitalized patients with different underlying diseases. Zhonghua Nei Ke Za Zhi. 2018;57(6):429-34
Lewis TC, Cortes J, Altshuler D, Papadopoulos J. Venous thromboembolism prophylaxis: a narrative review with a focus on the high-risk critically ill patient. J Intensive Care Med. 2019;34(11-12):877-88
Oh DK, Song JM, Park DW, Oh SY, Ryu JS, Lee J, et al. The effect of a multidisciplinary team on the implementation rates of major diagnostic and therapeutic procedures of chronic thromboembolic pulmonary hypertension. Heart Lung. 2019;48(1):28-33
Ten-Cate V, Prins MH. Secondary prophylaxis decision-making in venous thromboembolism: interviews on clinical practice in thirteen countries. Res Pract Thromb Haemost. 2017;1(1):41-8
Houghton DE, Lekah A, Macedo TA, Hodge D, Saadiq RA, Little Y, et al. Resolution of acute lower extremity deep vein
Buller HR, Ten Cate-Hoek AJ, Hoes AW, et al. Safely ruling out deep venous thrombosis in primary care. Ann Intern Med. 2009. 150(4):229-35
Houghton DE, Lekah A, Macedo TA, Hodge D, Saadiq RA, Little Y, et al. Resolution of acute lower extremity deep vein thrombosis with rivaroxaban compared to warfarin. J Thromb Thrombolysis. 2020;49(2):199-205
Farhan A, Bukhari M, Umar J, Raza MA. Oral Rivaroxaban in Symptomatic Deep Vein Thrombosis. J Coll Physicians Surg Pak. 2019;29(9):814-818
Al Khateep, Zaid YM, Salim NA, Osama RF. Comparative study of safety and effectiveness of rivaroxaban and warfarin in patients with acute deep venous thrombosis. Egyptian J Surgery. 2019;38(2):245
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Safi Ullah, Durkho Atif, Aliena Badshah, Muhammad Shadab Aslam Khan4
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
